X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (46) 46
humans (45) 45
female (30) 30
male (29) 29
middle aged (28) 28
index medicus (24) 24
aged (23) 23
adult (22) 22
chemotherapy (18) 18
cancer (17) 17
aged, 80 and over (15) 15
antineoplastic combined chemotherapy protocols - therapeutic use (10) 10
survival (10) 10
analysis (9) 9
lung neoplasms - drug therapy (9) 9
lung neoplasms - genetics (9) 9
neoplasm staging (9) 9
animals (8) 8
breast cancer (8) 8
carcinoma, non-small-cell lung - drug therapy (8) 8
deoxycytidine - analogs & derivatives (8) 8
gefitinib (8) 8
lung cancer (8) 8
lung neoplasms - pathology (8) 8
prognosis (8) 8
treatment outcome (8) 8
apoptosis (7) 7
carcinoma, non-small-cell lung - genetics (7) 7
carcinoma, non-small-cell lung - pathology (7) 7
deoxycytidine - administration & dosage (7) 7
disease-free survival (7) 7
hematology, oncology and palliative medicine (7) 7
lung cancer, non-small cell (7) 7
mice (7) 7
paclitaxel (7) 7
carcinoma, non-small-cell lung - mortality (6) 6
dna-binding proteins - genetics (6) 6
expression (6) 6
lung neoplasms - mortality (6) 6
metastasis (6) 6
mutation (6) 6
tumor cells, cultured (6) 6
tumors (6) 6
young adult (6) 6
antineoplastic agents - adverse effects (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
basic helix-loop-helix transcription factors (5) 5
breast-cancer (5) 5
carcinoma, squamous cell - pathology (5) 5
care and treatment (5) 5
disease progression (5) 5
dna methylation (5) 5
health aspects (5) 5
medical prognosis (5) 5
medicine, research & experimental (5) 5
methylation (5) 5
respiratory system (5) 5
studies (5) 5
survival analysis (5) 5
thai (5) 5
therapy (5) 5
transcription factors - genetics (5) 5
adolescent (4) 4
asia (4) 4
biomarkers, tumor - genetics (4) 4
cancer research (4) 4
cancer therapies (4) 4
carboplatin - administration & dosage (4) 4
cell line, tumor (4) 4
double-blind method (4) 4
gemcitabine (4) 4
gene (4) 4
gene expression regulation, neoplastic (4) 4
genes, tumor suppressor (4) 4
kaplan-meier estimate (4) 4
medicine & public health (4) 4
molecular sequence data (4) 4
multicenter (4) 4
nasopharyngeal neoplasms - genetics (4) 4
neoplasms. tumors. oncology. including cancer and carcinogens (4) 4
nsclc (4) 4
open-label (4) 4
patients (4) 4
prospective studies (4) 4
protein tyrosine phosphatase, non-receptor type 6 - genetics (4) 4
randomized-trial (4) 4
receptor, epidermal growth factor - antagonists & inhibitors (4) 4
serum (4) 4
signal transduction (4) 4
tamoxifen (4) 4
time factors (4) 4
adenocarcinoma (3) 3
adenocarcinoma - genetics (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
antineoplastic agents - therapeutic use (3) 3
asian continental ancestry group (3) 3
asians (3) 3
bevacizumab (3) 3
biochemistry & molecular biology (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. e15078 - e15078
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. e19099 - e19099
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 777 - 786
Summary Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly... 
Hematology, Oncology and Palliative Medicine | PHASE-III TRIAL | CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | GEFITINIB | MULTICENTER | THERAPY | NSCLC | ONCOLOGY | ADENOCARCINOMA | OPEN-LABEL | EGFR | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Time Factors | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Administration, Intravenous | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Care and treatment | Chemotherapy | Clinical trials | Lung cancer, Non-small cell | Antineoplastic agents | Tumors | Cancer | Index Medicus
Journal Article
International Journal of Clinical Oncology, ISSN 1341-9625, 8/2014, Volume 19, Issue 4, pp. 586 - 592
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2011, Volume 29, Issue 21, pp. 2866 - 2874
Purpose The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and carboplatin/paclitaxel in previously untreated never-smokers and light... 
TRIAL | CHEMOTHERAPY-NAIVE PATIENTS | FACTOR-RECEPTOR GENE | PLACEBO | ONCOLOGY-GROUP | ONCOLOGY | TYROSINE KINASE | SENSITIVITY | EGFR MUTATIONS | MOLECULAR PREDICTORS | PREVIOUSLY TREATED PATIENTS | Immunohistochemistry | Lung Neoplasms - drug therapy | Predictive Value of Tests | Adenocarcinoma - pathology | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Time Factors | Gefitinib | Odds Ratio | Paclitaxel - administration & dosage | Adenocarcinoma - chemistry | Precision Medicine | ErbB Receptors - antagonists & inhibitors | Lung Neoplasms - chemistry | Risk Assessment | Risk Factors | Carboplatin - administration & dosage | In Situ Hybridization, Fluorescence | Logistic Models | Survival Rate | Adenocarcinoma - drug therapy | Biomarkers, Tumor - genetics | Mutation | Carcinoma, Non-Small-Cell Lung - chemistry | Adenocarcinoma of Lung | ErbB Receptors - genetics | Lung Neoplasms - pathology | Patient Selection | Female | Adenocarcinoma - genetics | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Biomarkers, Tumor - analysis | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Gene Dosage | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | ErbB Receptors - analysis | Adenocarcinoma - mortality
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. e21206 - e21206
Journal Article
Asian Pacific Journal of Cancer Prevention, ISSN 1513-7368, 11/2016, Volume 17, Issue 11, pp. 4917 - 4920
For advanced non-small-cell lung cancer (NSCLC) cases, a platinum-based regimen is the first-line chemotherapy treatment. The excision repair... 
Non-small-cell lung cancer | Response to chemotherapy | SNP | Platinum | ERCC1 | lung cancer | response to chemotherapy | platinum | non-small-cell
Journal Article
by Mok, Tony and Mok, Tony S K and Wu, Yilong and Wu, Yi-Long and Kudaba, Iveta and Kowalski, Dariusz M and Kowalski, Dariusz and Cho, Byoung Chul and Turna, Hande and Turna, Hande Z and Castro, Hugo and Castro, Gilberto and Srimuninnimit, Vichien and Laktionov, Konstantin and Laktionov, Konstantin K and Bondarenko, Igor and Kubota, Kaoru and Lubiniecki, Gregory M and Zhang, Jin and Zhang, Li and Zhang, Xin and Kush, Debra and Lopes, Valeria and Lopes, Gilberto and Adamchuk, Grigory and Ahn, Myung-Ju and Alexandru, Aurelia and Altundag, Ozden and Alyasova, Anna and Andrusenko, Orest and Aoe, Keisuke and Araujo, Antonio and Aren, Osvaldo and Arrieta Rodriguez, Oscar and Ativitavas, Touch and Avendano, Oscar and Barata, Fernando and Barrios, Carlos Henrique and Beato, Carlos and Bergstrom, Per and Betticher, Daniel and Bolotina, Larisa and Botha, Michiel and Buddu, Sayeuri and Caglevic, Christian and Cardona, Andres and Cay Senler, Filiz and Cerny, Carlos Alexandre Sydow and Cesas, Alvydas and Chan, Gee-Chen and Chang, Jianhua and Chen, Xi and Chen, Gongyan and Cheng, Ying and Cheng, Susanna and Cherciu, Nelly and Chiu, Chao-Hua and Cicenas, Saulius and Ciurescu, Daniel and Cohen, Graham and Costa, Marcos Andre and Danchaivijitr, Pongwut and De Angelis, Flavia and de Azevedo, Sergio Jobim and Dediu, Mircea and Deliverski, Tsvetan and De Marchi, Pedro Rafael Martins and de The Bustamante Valles, Flor and Ding, Zhenyu and Doganov, Boyan and Dreosti, Lydia and Duarte, Ricardo and Edusma-Dy, Regina and Emelyanov, Sergey and Erman, Mustafa and Fan, Yun and Fein, Luis and Feng, Jifeng and Fenton, David and Fernandes, Gustavo and Ferreira, Carlos and Franke, Fabio Andre and Freitas, Helano and Fujisaka, Yasuhito and Galindo, Hector and Galvez, Christina and Ganea, Doina and Gil, Nuno and Girotto, Gustavo and Goker, Erdem and Goksel, Tuncay and Gomez Aubin, Gonzalo and Gomez Wolff, Luis and Griph, Hakan and Gumus, Mahmut and Hall, Jacqueline and Hart, Gregory and Havel, Libor and He, Yong and He, Jianxing and ... and KEYNOTE-042 Investigators
The Lancet, ISSN 0140-6736, 05/2019, Volume 393, Issue 10183, pp. 1819 - 1830
Journal Article
Asian Pacific journal of cancer prevention : APJCP, ISSN 1513-7368, 2016, Volume 17, Issue 11, pp. 4917 - 4920
For advanced non-small-cell lung cancer (NSCLC) cases, a platinum-based regimen is the first-line chemotherapy treatment. The excision repair... 
Journal Article
Asian Pacific journal of cancer prevention : APJCP, ISSN 1513-7368, 2016, Volume 17, Issue 9, pp. 4391 - 4394
Background: Platinum-based regimens are effective treatments for advanced non-small cell lung cancer (NSCLC), but the five-year survival rate is still less... 
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 07/2015, Volume 21, Issue 14, pp. 3196 - 3203
Journal Article
Neoplasia, ISSN 1476-5586, 09/2006, Volume 8, Issue 9, pp. 733 - 746
The development of head and neck squamous cell carcinoma (HNSCC) involves the accumulation of genetic and epigenetic alterations in tumor-suppressor proteins,... 
cytokine | gene expression regulation | transcription factor | Oral cancer | IL-6 | Gene expression regulation | Transcription factor | Cytokine | SURVIVAL | CONSTITUTIVE ACTIVATION | KINASE | PROLIFERATION | INTERLEUKIN-6 | CYTOKINE EXPRESSION | GROWTH-FACTOR RECEPTOR | ONCOLOGY | LIVER DEGENERATION | PROSTATE-CANCER | IN-VIVO | oral cancer
Journal Article
Breast Cancer: Targets and Therapy, ISSN 1179-1314, 08/2016, Volume 8, pp. 149 - 155
Tamoxifen (TAM) is used in breast cancer treatment, but interindividual variabilities in TAM-metabolizing enzymes exist and have been linked to single... 
SNPs | Oncology | Pharmacogenetics | Antihormone | CYP450 | Pharmacogenomics | Cytochrome | Enzymes | Data analysis | Estrogen | Systematic review | Whites | Breast cancer | Gene expression | Metabolism | Patients | Clinical outcomes | Studies | Genotype & phenotype | Metabolites | Womens health | Software | Thermal cycling | Deoxyribonucleic acid--DNA | Asians
Journal Article